CAMBRIDGE, Massachusetts (REUTERS) – Moderna Inc said on Monday (March 15) it had dosed the first patients in an early-stage study of a new Covid-19 vaccine candidate for evaluation as a next-generation shot.

The company said its new candidate, mRNA-1283, could potentially be stored in refrigerators instead of freezers, making it easier to distribute, especially in developing countries.

The early-stage study will assess the safety and immunogenicity of mRNA-1283 at three dose levels, and will be given to healthy adults either as a single dose or in two doses 28 days apart, the company said.

Last week, Moderna began dosing the first participants in a study testing its Covid-19 booster vaccine candidates.

Join ST’s Telegram channel here and get the latest breaking news delivered to you.

Source: Read Full Article